Compare ARL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARL | ZNTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7M | 289.0M |
| IPO Year | 1999 | 2020 |
| Metric | ARL | ZNTL |
|---|---|---|
| Price | $21.12 | $4.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 11.6K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 206.59 | 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,014,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.70 | N/A |
| 52 Week Low | $12.42 | $1.15 |
| 52 Week High | $24.44 | $6.95 |
| Indicator | ARL | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 59.31 |
| Support Level | $14.97 | $3.53 |
| Resistance Level | N/A | $6.95 |
| Average True Range (ATR) | 1.10 | 0.38 |
| MACD | 0.68 | 0.10 |
| Stochastic Oscillator | 67.14 | 60.37 |
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.